von Rohr, Sophie
Knitza, Johannes http://orcid.org/0000-0001-9695-0657
Grahammer, Manuel http://orcid.org/0000-0003-1560-4459
Schmalzing, Marc http://orcid.org/0000-0002-3289-2299
Kuhn, Sebastian http://orcid.org/0000-0002-8031-2973
Schett, Georg http://orcid.org/0000-0001-8740-9615
Ramming, Andreas http://orcid.org/0000-0002-7003-501X
Labinsky, Hannah http://orcid.org/0000-0001-5762-9182
Funding for this research was provided by:
Novartis Pharma GmbH, Nürnberg
Deutsche Forschungsgemeinschaft (DFG - FOR 2886 "PANDORA")
Universitätsklinikum Würzburg
Article History
Received: 23 May 2023
Accepted: 1 July 2023
First Online: 24 July 2023
Declarations
:
: JK has received research support from and has received consulting/speaker’s fees from Novartis Pharma GmbH and ABATON. MG is founder and shareholder of ABATON GmbH. SK is founder and shareholder of MED.digital GmbH. The other authors have disclosed no conflicts of interest.
: The study was approved by the regional ethics review board in Erlangen, Germany (Reg no. 21–357-B). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual respondents included in the study.
: All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria.